-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 19, Fosun Pharma announced that its subsidiary had obtained the exclusive rights to an oncology drug in Chi.
According to the announcement, Fosun Pharma USA, a subsidiary of Fosun Pharma, has been licensed by VerImmune to use its proprietary technology and technology in the region .
mainland China, Hong Kong, Macau and Taiwan) and in the field .
the treatment, mitigation, diagnosis or prevention of human or animal disease.
Exclusive clinical development, import and commercialization of the virus-like particle-based tumor immunotherapy drug VERI-10 According to the data, VERI-101 is a tumor immune drug based on virus-like particles, which can fight and treat cancer by guiding and activating the immune memory generated by the human body against cytomegalovirus to tumo.
Based on studies to date, the drug shows potential as a single agent as well as in combination with immune point inhibitors against a variety of solid tumo.
As agreed, Fosun Pharma USA may sublicense its rights granted under this Agreement to its affiliates or other qualified third parti.
Fosun Pharma USA shall pay VerImmune up to $27 million in upfront payment, preclinical milestones, clinical development registration milestones, and sales milestones as agreed upon for the licensed produ.
The introduction of innovative drug projects from foreign companies is a model for the development of innovative drugs by many compani.
It is understood that in the past two years, the domestic license in transaction has been listed year by year, and it is predicted that it will continue to be hot in the next three yea.
According to statistics, in 2021, there will be a total of 128 license in transactions in China's pharmaceutical industry, most of which are introduced through the rights and interests of innovative drug projec.
Among them, Zai Lab performed well with 6 transactions with a total value of over US$68 billion.
In addition, the introduction of technology has also increased significantly compared to 2020, which is also a new trend in the Chinese pharmaceutical license in mod.
It is reported that in 2021, the first batch of products under the license-in model has entered the NDA and even the market sta.
Through the license-in foreign innovative drugs in the late clinical stage, conducting bridging clinical trials in China or participating in international multi-center clinical trials can greatly improve the Shorten the development cycle and accelerate the entry of new drugs into the Chinese mark.
Entering 2022, license in transactions are also emergi.
According to incomplete statistics, in January 2022, there were 6 license in transactions in domestic pharmaceutical companies; in February, there were no less than 5 license in transactions in domestic pharmaceutical companies; in March There are also no less than 7 license in transactio.
Among them, Huadong Medicine introduced 5 innovative products through 3 license in transactions in February, covering the fields of anti-tumor and autoimmune diseases, with a transaction amount of US$21 billion (almost the total amount of transactions this mont.
In March, Eli Lilly and Innovent announced the deepening of their strategic cooperation, granting Innovent the exclusive commercialization rights to import, sell, promote and distribute ramucirumab and sepretinib in mainland China, pending approv.
After the HCC indications of mosimumab and the non-small cell lung cancer indications of sapritinib are approved for registration, Innovent will pay Lilly a total of $45 million down payment, and Innovent will be solely responsible for th.
Pricing, importation, marketing, distribution and sales promotion of the two products; grants Innovent Biothe priority negotiating rights for future commercialization of Pirtobrutinib in mainland Chi.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
According to the announcement, Fosun Pharma USA, a subsidiary of Fosun Pharma, has been licensed by VerImmune to use its proprietary technology and technology in the region .
mainland China, Hong Kong, Macau and Taiwan) and in the field .
the treatment, mitigation, diagnosis or prevention of human or animal disease.
Exclusive clinical development, import and commercialization of the virus-like particle-based tumor immunotherapy drug VERI-10 According to the data, VERI-101 is a tumor immune drug based on virus-like particles, which can fight and treat cancer by guiding and activating the immune memory generated by the human body against cytomegalovirus to tumo.
Based on studies to date, the drug shows potential as a single agent as well as in combination with immune point inhibitors against a variety of solid tumo.
As agreed, Fosun Pharma USA may sublicense its rights granted under this Agreement to its affiliates or other qualified third parti.
Fosun Pharma USA shall pay VerImmune up to $27 million in upfront payment, preclinical milestones, clinical development registration milestones, and sales milestones as agreed upon for the licensed produ.
The introduction of innovative drug projects from foreign companies is a model for the development of innovative drugs by many compani.
It is understood that in the past two years, the domestic license in transaction has been listed year by year, and it is predicted that it will continue to be hot in the next three yea.
According to statistics, in 2021, there will be a total of 128 license in transactions in China's pharmaceutical industry, most of which are introduced through the rights and interests of innovative drug projec.
Among them, Zai Lab performed well with 6 transactions with a total value of over US$68 billion.
In addition, the introduction of technology has also increased significantly compared to 2020, which is also a new trend in the Chinese pharmaceutical license in mod.
It is reported that in 2021, the first batch of products under the license-in model has entered the NDA and even the market sta.
Through the license-in foreign innovative drugs in the late clinical stage, conducting bridging clinical trials in China or participating in international multi-center clinical trials can greatly improve the Shorten the development cycle and accelerate the entry of new drugs into the Chinese mark.
Entering 2022, license in transactions are also emergi.
According to incomplete statistics, in January 2022, there were 6 license in transactions in domestic pharmaceutical companies; in February, there were no less than 5 license in transactions in domestic pharmaceutical companies; in March There are also no less than 7 license in transactio.
Among them, Huadong Medicine introduced 5 innovative products through 3 license in transactions in February, covering the fields of anti-tumor and autoimmune diseases, with a transaction amount of US$21 billion (almost the total amount of transactions this mont.
In March, Eli Lilly and Innovent announced the deepening of their strategic cooperation, granting Innovent the exclusive commercialization rights to import, sell, promote and distribute ramucirumab and sepretinib in mainland China, pending approv.
After the HCC indications of mosimumab and the non-small cell lung cancer indications of sapritinib are approved for registration, Innovent will pay Lilly a total of $45 million down payment, and Innovent will be solely responsible for th.
Pricing, importation, marketing, distribution and sales promotion of the two products; grants Innovent Biothe priority negotiating rights for future commercialization of Pirtobrutinib in mainland Chi.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
